Brief: Labcorp Reaffirms 2026-2029 Outlook Including 5%-8% Compound Annual Revenue Growth
22/09/2026 22:14
BRIEF-Labcorp Reaffirms 2026-2029 Outlook Including 5%-8% Compound Annual Revenue Growth Sept 23 (Reuters) - Labcorp Holdings Inc. LH.N:
LABCORP - REAFFIRMS 2026-2029 OUTLOOK INCLUDING 5%-8% COMPOUND ANNUAL REVENUE GROWTH - SEC FILING
LABCORP - EXPECTS COMPOUND ANNUAL ADJUSTED EPS GROWTH OF 8.5%-11.5% IN 2026-29- SEC FILING
Further company coverage: LH.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Labcorp Holdings
See all newsBrief: Charles River, Labcorp, And FDA Collaborate To Validate New Preclinical Methods For Abuse Potential Assessment
Brief: Labcorp Declares Quarterly Dividend
Myriad jumps after agreeing to sell prenatal health testing business
Brief: Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp
Live Markets: Split US congress after 2026 midterms could boost healthcare stocks, Mizuho says